Results 291 to 300 of about 1,557,410 (381)

Ultra-High-Frequency ECG in Cardiac Pacing and Cardiac Resynchronization Therapy: From Technical Concept to Clinical Application. [PDF]

open access: yesJ Cardiovasc Dev Dis
Nguyên UC   +11 more
europepmc   +1 more source

Long-Term His-Bundle Pacing and Cardiac Function

open access: bronze, 2000
Melvin M. Scheinman, Leslie A. Saxon
openalex   +1 more source

Quantitative Evaluation of a Directly Depolarized Area Induced by High-Output Pacing on the Cardiac Muscle

open access: bronze, 2000
Masahiko Moriguchi   +6 more
openalex   +2 more sources

Reversal of Pacing-Induced Cardiomyopathy Following Cardiac Resynchronization Therapy.

open access: yesJACC Clinical Electrophysiology, 2018
S. Khurshid   +9 more
semanticscholar   +1 more source

Public preferences regarding slow codes in critical care

open access: yesBioethics, EarlyView.
Abstract The term slow code refers to an intentional reduction in the pace or intensity of resuscitative efforts during a medical emergency. This can be understood as an intermediate level between full code (full resuscitation efforts) and no code (no resuscitation efforts) and serves as a symbolic gesture when intervention is considered medically ...
Philipp Sprengholz
wiley   +1 more source

Wearable sensors in paediatric neurology

open access: yesDevelopmental Medicine &Child Neurology, EarlyView.
Types of signals monitored in children's natural environments using wearable sensors, and their associated applications in various paediatric neurological conditions. Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16267 Abstract Wearable sensors have the potential to transform diagnosis, monitoring, and management of children ...
Camila González Barral, Laurent Servais
wiley   +1 more source

A review of the safety of sodium‐glucose co‐transporter‐2 inhibitors

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract The development of sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors represents a major turning point in the effort to preserve kidney function and prevent cardiovascular events and heart failure hospitalisations in those at high risk. These agents have now transcended their original glucose‐lowering indication and provide a range of clinical
Daniel Vincent O'Hara, Meg J. Jardine
wiley   +1 more source

Home - About - Disclaimer - Privacy